Novartis AG (NVS)

Total return at 5 years: 11.7%/year = 8.8% appreciation + 2.9% dividend. The target price ($244) is ex-dividend; the $28 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $256 · Multiples $220) exceeds the market price ($160).

Today — fairly valued: at $160 trades ~27.3% below its value discounted to today (~$220); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — Infravalorado: the target price ($244) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$140.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($160) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-3.3%/year) than we project (6.5%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$14.9 bn of owner earnings in year 5 (vs ~$24.1 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 is the fiscal year ended December 31, 2025 (Novartis files an annual 20-F and reports its quarters via 6-K without XBRL, so no properly tagged TTM exists — the annual-reporter convention). 2025 revenue (US$54.53bn, +8.4%) remains driven by double-digit growth in Oncology (+18%), Immunology (+11%) and Neuroscience (+26%) — with Cosentyx, Kesimpta, Kisqali, Pluvicto and Scemblix as the engines — which offset the decline in Established Brands (-7%) after Entresto's U.S. exclusivity loss in July 2025. The reported growth breakdown (volume +15pp, generic competition -6pp, price -1pp) shows the engine is volume, not price, and that 2026 absorbs the first full year without Entresto's U.S. protection. The base path starts near the recent trajectory (7.7%-10.7% over the last three fiscal years) and decelerates smoothly toward ~5.5% by year 5, a level consistent with a mature portfolio diversified across four core therapeutic areas. GAAP operating margin (32.4% in 2025) gradually expands toward ~36% by year 5 as the legal and restructuring charges that today separate GAAP results from the non-GAAP Core result (40.1% in 2025) dilute. Sustained net buybacks (~3.8%/year over the last three fiscal years, US$8.9bn in 2025 under a program of up to US$10bn in effect since July 2025) are modeled as an explicit reduction in share count — the same path across all three scenarios — because Novartis distributes via a growing dividend and buybacks nearly 100% of its free cash flow, with no excess cash to accumulate. No explicit numeric guidance for fiscal year 2026 was found in the available July 2026 6-K (it only carries the interim financial statements, without the narrative press release with quantitative guidance); the year-1 path is therefore anchored to the recent historical trajectory, disclosing the absence of guidance rather than inventing it. The bear scenario stresses year 1 (growth of just 4%, with Medicare/IRA pricing pressure on Cosentyx, Kisqali and Xolair) and the bull scenario assumes strong execution of the pipeline and recent acquisitions (Anthos, Regulus, Tourmaline Bio, Avidity Biosciences, with Myricx Bio announced in July 2026).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $244 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $160, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $244 in 5 years plus $28 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $220. Against the current market price ($160), the margin of safety is 27.3% (trades below the maximum → there is margin) and the total return at that price would be 11.7% annually.

• Entry multiple. 22×x EV/NOPAT today.
• Position within the archetype band. 18x in the base case, the midpoint of the pharmaceutical band [14x,22x].
• Terminal multiple earnings yield. 1/18x ≈ 5.6%, consistent with a business still growing at year 5 (~5.5%).
• Margin of safety today. It trades at a real discount to value, though short of the required margin of safety.
• Expected 5-year return. +12% annually at market price.
• Dividend's share of the return. The dividend contributes +3% of the total estimated 5-year return, on a current yield of ~3%.
• Sensitivity to the terminal multiple. Bear at 14x (band floor) and Bull at 21x (near the ceiling) bound the outcome range without forcing the multiple below the band floor.

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (117%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs. the 10% bar. ~21.95% on real invested capital from the balance sheet (equity + debt − cash), well above the 10% bar.
• Cash generation. Free cash flow of US$17.6bn in 2025 (+8% year over year), consistent with reported earnings.
• D&A quality. US$4.07bn of the US$5.33bn of 2025 D&A is amortization of acquisition intangibles (non-cash, with no equivalent physical replacement capex); disclosed so as not to confuse the profitability reading.
• Cash conversion. Free cash flow (US$17.6bn) above net income (US$14.0bn) in 2025.
• Reinvestment runway. Capex of only US$1.55bn in 2025 (2.8% of revenue); growth is mainly funded via organic R&D and complementary M&A, not capital-intensive physical capex.
• Effective tax rate. 14.6% in 2025, favored by the geographic mix of earnings; the real effective rate from the filing is used, not a 'typical' rate.
• Serial acquirer. Invested capital carries the price paid in acquisitions (goodwill + intangibles), which raises ROIC's denominator; the ~22% return already reflects that effect and remains high.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

2025 revenue growth (+8% at constant currency) breaks down into volume +15 percentage points, generic competition -6pp and price -1pp: the engine is prescription volume of the growth products (Cosentyx, Kesimpta, Kisqali, Pluvicto, Scemblix), not price, which in fact subtracts. Generic competition (-6pp) mainly reflects Entresto's erosion after losing U.S. market exclusivity in July 2025, whose European regulatory protection expires in November 2026.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (31-dic-2025): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Reported growth. +8.4% in 2025, within the band of the last three fiscal years (7.7%-10.7%).
• Growth engine. Oncology, Immunology and Neuroscience (Cosentyx, Kesimpta, Kisqali, Pluvicto, Scemblix) offset the decline in Established Brands.
• Patent erosion. Entresto lost U.S. exclusivity in July 2025; its European protection expires in November 2026.
• Pipeline. 18 approvals, 13 regulatory filings and 17 molecules advancing to late-stage in 2025, per the company's own management report.
• M&A as a growth lever. Recent acquisitions (Anthos, Regulus, Tourmaline Bio, Avidity Biosciences, announced Myricx Bio) broaden the pipeline beyond organic R&D.
• Quantitative guidance available. The available July 2026 6-K only carries interim financial statements, without the narrative press release with quantitative guidance for 2026; no explicit guidance figure was found.
• Sustainability of the path. Growth decelerates smoothly from ~8% to ~5.5% by year 5 in the base case, a level consistent with a mature portfolio.

• Demand recurrence. Medicines for chronic and oncological conditions with recurring demand for as long as patent protection lasts.
• Product differentiation. Portfolio of innovative, patent-protected molecules, not commodities.
• Pricing power. 2025 reported growth came from volume (+15pp), with price subtracting (-1pp) — pricing power is limited by regulatory and payer pressure.
• Operating leverage. Margins expand with scale (Core +140bp year over year in 2025) as the younger brands grow.
• Recession behavior. Demand for medicines is defensive against the general economic cycle.
• Customer concentration. The three largest global customers accounted for ~18%, 13% and 7% of 2025 net sales.
• Sector capital cycle. Active M&A across the sector (17 own transactions in 2025) keeps competition for innovation assets high.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net debt / EBITDA 1.0x
• ✓Interest coverage (EBIT / interest)15.4x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 117% of ROIC
• ✓Value creation (ROIC − 10% bar)+12pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.3x — no over-investment
• !Float / working capitalConsumes cash $1.6 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 2.0% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Financial debt of US$33.54bn against equity of US$46.55bn and cash of US$11.44bn as of December 2025 — moderate leverage.
• Liquidity. Cash of US$11.44bn plus current assets of US$30.46bn against current liabilities of US$27.28bn.
• Cost of recent M&A. Intangibles rose US$12.7bn in the first half of 2026 from the acquisitions of Avidity Biosciences, Pikavation Therapeutics and Excellergy.
• Interest coverage. Operating income of US$17.64bn in 2025 against interest expense of US$1.14bn — ample coverage.
• Pending acquisition commitment. Myricx Bio (announced July 2026): up to US$1.5bn in total payments (US$1.1bn at closing plus up to US$0.4bn in milestones).
• Legal contingencies. Gilenya marketing-practices litigation in the discovery stage since March 2026, with no materiality quantified by the company in the filing.

• Minimum ownership required. The executive team and the board are subject to minimum share-ownership requirements (a multiple of base salary for executives; 30,000/5,000 shares for directors).
• Incentives tied to financial KPIs. 60% of the annual incentive depends on sales, Core operating income and free cash flow as % of sales.
• Capital allocation. Growing dividend + sustained buybacks (~US$8.9bn in 2025) funded from operating cash flow, without leveraging the balance sheet to return capital.
• M&A track record. 17 transactions closed in 2025 plus Avidity Biosciences in the first half of 2026; the filing explicitly warns of the risk of not successfully integrating these acquisitions.
• Transparency on litigation. The filing details the Gilenya investigation and its procedural status (discovery stage since March 2026) rather than omitting it.

• The Sandoz spin-off (2023) is still recent: part of analyst coverage and the market narrative remains anchored to the prior consolidated profile
• Entresto's erosion has already materialized and became visible in the second half of 2025, which can read as more severe than it is given that the rest of the portfolio already offsets it on a consolidated basis
• Ongoing regulatory/legal investigation into Gilenya marketing practices (in the discovery stage since March 2026), which introduces legal noise without quantified materiality in the filing

No single, decisive forced-selling catalyst was identified in the available material (the FY2025 20-F and the July 2026 6-K, which only carries the interim financial statements without the narrative press release). A partial missing-buyers reading (post-spin-off coverage, ongoing litigation with no figure) is the most defensible one; it is not ruled out that the market is correctly pricing Entresto's erosion risk.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -2%/year (-8% total): the margin of safety protects the downside. The bull (+18%/year, +126% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Loss of intellectual-property exclusivity, already materialized in the historically largest product. Entresto lost U.S. exclusivity in July 2025 with a substantial sales decline in the second half; its European protection expires in November 2026.
• Pricing and reimbursement pressure in the U.S.. December 2025 voluntary agreement on comparable launch prices among countries, plus Medicare price negotiation (IRA) on Cosentyx, Kisqali and Xolair starting 2028.
• M&A integration risk. Explicit risk in the filing of failing to successfully integrate Anthos, Regulus, Tourmaline Bio or Avidity Biosciences, or of failing to achieve expected synergies.
• Competitive lag in AI applied to R&D. The filing flags the risk of falling behind if rivals adopt more sophisticated AI models in drug discovery and development.
• Customer concentration. The three largest global customers accounted for ~18%, 13% and 7% of 2025 net sales (16%, 12% and 6% of receivables), with a trend of distributor consolidation.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 7% at a multiple/growth of 3.4 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 5% (EBIT/EV) + ROIC 22% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -3% vs our 7%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -6%/yr, bull-scenario ceiling +15%/yr over 5y: reasonable asymmetry, without an ample cushion.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, efficient scale, switching costs, cost advantage → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -3%, within what we project (7%) — the story squares with the numbers.